CCS
CYTK icon

Concentric Capital Strategies’s Cytokinetics CYTK Stock Holding History

Concentric Capital Strategies’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,788
Closed -$483K – 285
2025
Q3 		$483K Buy
+8,788
New +$362K 0.02% 260
2024
Q3 		– Sell
-60,564
Closed -$3.28M – 301
2024
Q2 		$3.28M Buy
60,564
+20,357
+51% +$1.23M 0.16% 147
2024
Q1 		$2.82M Buy
+40,207
New +$3.11M 0.16% 149

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Concentric Capital Strategies's CYTK Position: Q4 2025 in Review

Concentric Capital Strategies sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 8,788 shares — an estimated $483K sold.

Concentric Capital Strategies first reported a position in CYTK in Q1 2024 and held it in 3 quarters. The position peaked at $3.28M in Q2 2024. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Concentric Capital Strategies reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Concentric Capital Strategies sold 8,788 Cytokinetics shares in Q4 2025, an estimated $483K.
  • Concentric Capital Strategies first reported a position in Cytokinetics in Q1 2024 and held it in 3 quarters.
  • Concentric Capital Strategies's Cytokinetics position peaked at $3.28M in Q2 2024.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Concentric Capital Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.